• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

Opinion
Video

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

Related Videos
Nihar Desai, MD, MPH
Dr Toon Van Gorp
Andrew Kuykendall, MD, Moffitt Cancer Center
Barry Byrne, MD
Giulio Cossu, MD
Dr Toon Van Gorp
5 experts are featured in this series
5 experts are featured in this series
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.